Venture-backed Celularity gets FDA approval for early trials of a brand-new cell treatment for COVID-19

by RJ Shara | Apr 2, 2020 | Startups

Celularity, the venture-backed developer of novel cell therapies for cancer treatments, has actually gotten a preliminary clearance from the Fda to begin early-stage scientific trials on a possible treatment for COVID-19. The business, which has raised a minimum of $290 million to date(according to Crunchbase), utilizes “Natural Killer”(NK )cell treatments to increase […]
NK cells are a type of white blood cell that are part of the body’s immune system. Unlike t-cells, which target specific pathogens, NK cells normally work to support the immune system by identifying and damaging cells in the body that appear to be stressed, either from an anomaly or an infection. There’s likewise the possibility that NK cells may not be able to detect which cells are contaminated with the coronavirus which causes COVID-19, rendering the therapy ineffective. …